GILD
Gilead Sciences, Inc.
NMS
$127.57
-3.53
(-2.69%)
Pullback · -1.49σ
132-Day TAO Zones
21 EMA
+1 ATR
+2 ATR
−2 ATR
—
O —
H —
L —
C —
—
—
Key statistics
Mkt cap
$158.4B
P/E ttm
17.4
Fwd P/E
13.3
Beta
0.33
Day range
$127.57
52w range
$116.88 – $157.29
Avg vol
6.1M
RSI(2)
6.3
ROE
43.4%
Net mgn
31.0%
FCF mgn
26.7%
Debt/Eq
0.95
Div yld
250.00%
Sector
Healthcare
Industry
Drug Manufacturers - General
Next earn
2026-08-06
Matrix setup grades
Long
—
score 20 · tech 20 / 80 · support 0 / 20
KC1 lower, -1.48 ATR from EMA21 · no notable pattern
- · KC1 lower stretch — light dip
- · Aligned with weak uptrend
Short
—
score 9 · tech 9 / 80 · support 0 / 20
below KC1 upper, -1.48 ATR from EMA21 · no notable pattern
Options · swing
See more →
CALL
$130
2026-07-17
$3.90
PUT
$130
2026-07-17
$6.72
Insider activity
See more →No Form 4 filings in the last 30 days.
Earnings
See more →- Last reported
- 2026-05-07
- EPS (act / est)
- 2.03 / 1.91
- Surprise
- +6.2%
- Next report
- 2026-08-06
About
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to tre…